Tlr4 sirna

Manufactured by GenePharma

Sourced in China

TLR4 siRNA is a laboratory reagent used to study the role of the Toll-like receptor 4 (TLR4) gene in cellular processes. It functions by targeting and silencing the expression of the TLR4 gene, allowing researchers to investigate the effects of TLR4 knockdown on various cellular functions and pathways.

Automatically generated - may contain errors

Lab products found in correlation

Lipofectamine 2000, by Thermo Fisher Scientific (1 mentions) Control oligonucleotide, by GenePharma (1 mentions) Mir 17 5p mimic, by GenePharma (1 mentions) Lipofectamine 2000 reagent, by Thermo Fisher Scientific (1 mentions) Opti mem, by Thermo Fisher Scientific (1 mentions) Gp transfect mate, by GenePharma (1 mentions) Lipofectamine 3000, by Thermo Fisher Scientific (1 mentions)

Spelling variants of this product

SiRNAs (565 citations) SiRNA-specific TLR4 (2 citations)

5 protocols using tlr4 sirna

TLR4 Knockdown in Cell Cultures

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells (1x10⁶) were transfected with 1.0 µg TLR4 small interfering (si) RNA5'-CCGGCCGCTGGTGTATCTTTGAATACTCGAGTATTCAAAGATACA CCAGCGGTTTTTG-3') or scrambled siRNA (si-con, 5'-CCGGCTCCGGGTGTATCGTTTAATACTCGAGTCTAT AGAAATACACCAGGGCTTTTTG-3') as a negative control (cat. no. sc-40260; Santa Cruz Biotechnology, Inc.) using Lipofectamine^® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's procedure for 24 h at 37˚C with 5% CO₂.
Post-transfection, cells were cultured in complete media for 48 h. TLR4-siRNAs were purchased from Shanghai GenePharma Co., Ltd. Transfection efficiency was verified 48 h later via RT-qPCR.

Ye Y., Wang P, & Zhou F. (2021). miR-489-3p inhibits TLR4/NF-κB signaling to prevent inflammation in psoriasis. Experimental and Therapeutic Medicine, 22(1), 744.

+ Open protocol

+ Expand

Transfection of TLR4 siRNAs and miR-17-5p Modulators

Check if the same lab product or an alternative is used in the 5 most similar protocols

Small interfering RNAs (TLR4 siRNAs), miR-17–5p mimics, and miR-17–5p inhibitors as well as their corresponding control oligonucleotides were purchased from GenePharma. Transfection was carried out by using Lipofectamine 2000 reagent (Invitrogen) based on the manufacturer's instructions. The oligonucleotide sequences of TLR4 siRNAs are listed in Table S1. Then the cells were collected for further study.

Chu Z., Huang Q., Ma K., Liu X., Zhang W., Cui S., Wei Q., Gao H., Hu W., Wang Z., Meng S., Tian L., Li H., Fu X, & Zhang C. (2023). Novel neutrophil extracellular trap-related mechanisms in diabetic wounds inspire a promising treatment strategy with hypoxia-challenged small extracellular vesicles. Bioactive Materials, 27, 257-270.

+ Open protocol

+ Expand

TLR4 Silencing and Nuciferine Pretreatment

Check if the same lab product or an alternative is used in the 5 most similar protocols

TLR4-siRNA, and negative control siRNA were obtained from GenePharma Co., Ltd. (Shanghai, China). For TLR4-siRNAtransfection, RAW264.7 cells (1 × 10⁵ cells mL^-1) were grown in six well culture-plates and allowed to reach approximately 60% confluence. Transfection was carried out in Opti-MEM medium with negative control siRNA (NC-siRNA), TLR4-siRNA through Lipofectamine^TM 2000 in accordance with the producer’s protocol. After 6 h, pretreatment with nuciferine (20 μg/mL) was performed for 1 h, LPS (1 μg/mL) was added for 6 h in the treatment group. Finally, cells were cleaved for further analysis.

Wu H., Yang Y., Guo S., Yang J., Jiang K., Zhao G., Qiu C, & Deng G. (2017). Nuciferine Ameliorates Inflammatory Responses by Inhibiting the TLR4-Mediated Pathway in Lipopolysaccharide-Induced Acute Lung Injury. Frontiers in Pharmacology, 8, 939.

+ Open protocol

+ Expand

TLR4 Silencing in H9C2 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

TLR4 siRNA (A10001, GenePharma, China) was used to inhibit TLR4 expression according to the manufacturer’s instructions. The sequences (5′-3′) are GCAGCAGGUCGAAUUGUAUTT; AUACAAUUCGACCUGCUGCTT. Briefly, H9C2 cells were plated into 6-well plates for 24 h, and the medium was replaced with Opti-MEM (31985070, Gibco, United States) 2 h before transfection. Subsequently, cells were transfected with 8 μl RNA oligo (Tlr4-rat-2571 or negative control) and 8 μl GP-transfect-Mate (G04009, GenePharma, China)/well for 6 h, followed by DMEM (10% FBS; no P/S) for 18 h instead. Proteins were extracted to check knockdown efficiency at 48 h after the transfection.

Li Y., Li X., Chen X., Sun X., Liu X., Wang G., Liu Y., Cui L., Liu T., Wang W., Wang Y, & Li C. (2022). Qishen Granule (QSG) Inhibits Monocytes Released From the Spleen and Protect Myocardial Function via the TLR4-MyD88-NF-κB p65 Pathway in Heart Failure Mice. Frontiers in Pharmacology, 13, 850187.

+ Open protocol

+ Expand

RAGE and TLR4 Silencing in MSCs

Check if the same lab product or an alternative is used in the 5 most similar protocols

Receptor for advanced glycation end products (RAGE) and TLR4 siRNA were designed and produced by GenePharma (Shanghai, China). RAGE siRNA sequence: sense: GCCAGAAAUUGUGGAUCCUTT; antisense: AGGAUCCACAAUUUCUGGCTT. TLR4 siRNA sequence: sense: GCUAUAGCUUCUCCAAUUUTT; antisense: AAAUUGGAGAAGCUAUAGCTT. Negative control (NC): sense: UUCUCCGAACGUGUCACGUTT; antisense: ACGUGACACGUUCGGAGAATT. The siRNA was transfected into MSCs using Lipofectamine 3000 (Invitrogen) according the manufacturer’s instructions. Briefly, MSCs were subjected to the mixture of siRNA and Lipofectamine 3000 reagent in serum-free DMEM medium for 6 h. And then medium was changed and the cells were harvested for the further experiments.

Wang S., Cai S., Zhang W., Liu X., Li Y., Zhang C., Zeng Y., Xu M., Rong R., Yang T., Shi B., Chandraker A., Yang C, & Zhu T. (2020). High-mobility group box 1 protein antagonizes the immunosuppressive capacity and therapeutic effect of mesenchymal stem cells in acute kidney injury. Journal of Translational Medicine, 18, 175.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!